Search - tctmd.com

Displaying 121 - 140 of 166

Sort: Relevancy | Date

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

News Conference News TCT 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Michael O'Riordan

November 06, 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

News Conference News HFSA 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

Michael O'Riordan

September 14, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

Heart Failure Patients With AF Benefit From Early Rhythm Control

News Conference News HRS 2021

Heart Failure Patients With AF Benefit From Early Rhythm Control

July 30, 2021

Optimizing Medical Therapy Before Clip Repair for MR? ‘This is Hard’

News Conference News TVT 2021

Optimizing Medical Therapy Before Clip Repair for MR? ‘This Is Hard’

July 27, 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

News Conference News ESC Heart Failure 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

July 06, 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

May 15, 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

May 15, 2021

Simple Tech Empowers HF Patients, Boosting Health: EPIC-HF and MyROAD

News Conference News AHA 2020

Simple Tech Empowers HF Patients, Boosting Health: EPIC-HF and MyROAD

November 18, 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

November 16, 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

News Conference News AHA 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

November 13, 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

October 09, 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

August 30, 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.